Biological and clinical abnormalities leading to cardiovascular disease during antiretroviral treatment in a university hospital in Abidjan

Abstract

Antiretroviral drugs are involved in the occurrence of adverse effects. In Côte d'Ivoire, HIV1 treatment protocols are non-nucleoside reverse transcriptase inhibitors based. No study has been undertaken in the country about cardiovascular risk. Thus, the objective of our study was to assess the prevalence of biological abnormalities and clinical markers of cardiovascular risk during antiretroviral therapy. We conducted a prospective cross-sectional study with 238 patients who were on antiretroviral treatment including nonnucleoside reverse transcriptase inhibitors for at least 6 months in the Pneumophtisiology department of the university hospital of Cocody (Abidjan). Metabolic syndrome was determined according to NCEP-ATP III criteria. Biological parameters investigated were: triglyceride, HDL cholesterol and LDL, glucose and clinical parameters: blood pressure and waist circumference. Eleven patients (4.62%) have a metabolic syndrome, 17.6% had hypertriglyceridemia. An increase in LDL cholesterol and lower HDL-cholesterol were found in both cases in 13.9% of patients and an atherogenic index greater than 4.5 in 5% of patients. Hyperglycemia occurred during antiretroviral therapy in 28% of the study population. Patients who developed hypertension and increased waist circumference during antiretroviral therapy were 9.75% and 15.5% respectively. Our results testify to the potential existence of a cardiovascular risk during the non-nucleoside inhibitor used.

Cytochrome P450 2B6 6 distribution among patients living with HIV in Burkina Faso

“…The recommended therapeutic combination is the combination of 3 ARVs (triple therapy) from two different classes of ARVs: "2NRTIs+1NNRTIs" combination: indicated only in the event of HIV1 infection; "2NRTIs+1PI" combination: indicated in case of HIV 2 infection, HIV1 and 2 co-infection. Antiretroviral drugs are involved in the occurrence of adverse effects (Kouakou-Siransy et al, 2015). Cytochrome genotyping of CYP2B6 in people living with HIV on antiretroviral therapy, particularly those on efavirenz therapy is important.…”

Comparaison de six méthodes de dosage indirect du cholestérol LDL chez des personnes vivant avec le VIH à Libreville

“…En effet, de la monothérapie à la multithérapie antirétroviral, les porteurs du VIH ont vu leur espérance de vie se prolonger (Althoff et al, 2016;OMS, 2016). Certains antirétroviraux (ARV) tels que la zidovudine (AZT), la stavudine (d4T), le lopinavir (LPV) et le ritonavir (RTV) pourraient, entre autres, entraîner une mortalité cardiovasculaire par la modification du profil lipidique (Vandhuick et al, 2004 ;Sabin et al, 2008 ;Kouakou-Siransy et al, 2015 ;Jain et al, 2018). L'un des paramètres lipidiques préconisé par les recommandations internationales et plus particulièrement par la Haute Autorité de Santé dans la prise en charge des patients à risque cardiovasculaire et des Personnes Vivant avec le VIH (PVVIH) est le dosage du cholestérol Low Density Lipoprotein (LDL) (Yeni, 2010).…”

Mutations du gène d’apoprotéine B100 au cours des dyslipidémies chez les sujets vivant avec le VIH

“…Ainsi, les patients séropositifs au VIH traités ou non présentent des anomalies du métabolisme lipidique ou dyslipidémies qui les exposent aux pathologies cardiovasculaires, en l'occurrence l'athérosclérose (Sawadogo et al, 2005). Il est aussi démontré une augmentation de l'apoprotéinémie B, principale apoprotéine contenue dans les lipoprotéines de basse densité (C-LDL et C-VLDL), accompagnée de l'augmentation de ces lipoprotéines (Judith et al, 2009) et la survenue de syndrome métabolique (Kouakou-Siransy et al, 2015).…”